GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

According to InvestingPro data, GSK maintains a strong financial health score, positioning it well for strategic acquisitions. IDRx's lead molecule, IDRX-42, is an investigational tyrosine kinase ...

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

Trump’s tariff threats and Kennedy’s anti-vaccine stance makes US a hostile environment for pharma companies ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

Today, GSK plc (LSE/NYSE: LON:GSK), a prominent pharmaceutical company with a market capitalization of $74.88 billion and impressive gross profit margins of 71.81%, announced the completion of its ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...